Format

Send to

Choose Destination
Mult Scler. 2013 Oct;19(11):1544-7. doi: 10.1177/1352458513498125. Epub 2013 Jul 25.

Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.

Author information

1
Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany.

Abstract

Neuromyelitis optica (NMO) predominantly affects women, some in childbearing age, and requires early therapeutic intervention to prevent disabling relapses. We report an anti-AQP4 antibody-seropositive patient who became pregnant seven months after low-dose (100 mg) rituximab application. Pregnancy showed no complications, and low-dose rituximab restarted two days after delivery resulted in neurological stability for 24 months. Remarkably, her otherwise healthy newborn presented with anti-AQP4 antibody and reduced B lymphocyte counts in umbilical cord blood, which normalized three months later. Confirming and extending previous reports, our case suggests that low-dose rituximab might be compatible with pregnancy and prevent rebound NMO disease activity postpartum.

KEYWORDS:

Neuromyelitis optica; antibody transfer; pregnancy; relapse prevention; rituximab

PMID:
23886825
DOI:
10.1177/1352458513498125
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center